Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug

• US 20100003332A1
• Filed: 07/26/2007
• Published: 01/07/2010
• Est. Priority Date: 07/27/2006
• Status: Abandoned Application

• Current Assignee: Amore Pacific Corporation
• Original Assignee: Amore Pacific Corporation
• Inventors: Bae, Joon Ho, Lee, Hyeok, Kim, Jung Ju, Lee, Jong Hwi
• Application Number:
  US12/375,232
• Publication Number:
  US 20100003332A1
• Time in Patent Office: Days
• US Class Current: 424/489
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61K 9/145 with organic compounds
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: A61K 9/5123 Organic compounds, e.g. fats, sugars
• CPC Class Codes: A61K 9/5161 Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
• CPC Class Codes: A61K 9/5192 Processes
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A powder comprising nanoparticles of a sparingly water-soluble drug prepared in accordance with the present invention exhibits enhanced bioavailability without generating adverse side effects caused by impurities, while the nano-particle size of the drug remains unchanged when administered. Accordingly, the powder can be useful for the development of a formulation of a sparingly water-soluble drug for oral and parenteral administration.

Claims

1. A method for preparing a powder composition comprising nanoparticles of a sparingly water-soluble drug comprising:

1) dispersing particles of the sparingly water-soluble drug, a surface stabilizer and a dispersion agent in a saturated aqueous solution of the dispersion agent to obtain a dispersion;

2) mixing and grinding the dispersion obtained in step

     1) to obtain a homogenized dispersion; and

3) centrifuging or high-pressure filtering the homogenized dispersion obtained in step

     2) to isolate a solid, and drying the solid to obtain a powder.

2. The method of claim 1, wherein the sparingly water-soluble drug is selected from the group consisting of non-steroidal anti-inflammatory drugs including acetaminophen, acetylsalicylic acid, ibuprofen, penbuprofen, fenoprofen, flubiprofen, indomethacin, naproxen, etorolac, ketoprofen, dexibuprofen, piroxicam and aceclofenac;

immunosuppressants or therapeutic agents for atopic dermatitis including cyclosporine, tacrolimus, rapamycin, mycophenylate and pimecrolimus;

calcium channel blockers including nifedipine, nimodipine, nitrendipine, nilvadipine, felodipine, amlodipine and isradipine;

angiotensin II receptor antagonists including valsartan, eprosartan, irebesartan, candersartan, telmisartan, olmesartan and losartan;

therapeutic agents for hyperlipidemia inhibiting cholesterol synthesis including atorvastatin, lovastatin, simvastatin, fluvastatin, rosuvastatin and pravastatin;

therapeutic agents for hyperlipidemia promoting cholesterol metabolism and secretion including gemfibrozil, fenofibrate, etofibrate and bezafibrate;

therapeutic agents for diabetes including pioglitazone, rosiglitazone and metformin;

lipase inhibitors including orlistat;

antifungal drugs including itraconazole, amphotericin B, terbinafine, nystatin, griseofulvin, fluconazole and ketoconazole;

liver protectors including biphenyl dimethyl dicarboxylate, silymarin and ursodesoxycholic acid;

therapeutic agents for digestive tract disease including sopharcone, omeprazole, pantoprazole, famotidine, itopride and mesalazine;

platelet aggregation inhibitors including cilostazol and clopidogrel;

therapeutic agents for osteoporosis including raloxifene;

antiviral agents including acyclovir, famciclovir, lamivudine and oseltamivir;

antibiotics including clarithromycin, ciprofloxacin and cefuroxime;

antiasthmatic drugs and antihistamines including pranlukast, budesonide and fexofenadine;

hormones including testosteron, prednisolone, estrogen, cortisone, hydrocortisone and dexamethasone;

antitumor agents including paclitaxel, docetaxel, paclitaxel derivatives, doxorubicin, adriamycin, daunomycin, campothecin, etoposide, teniposide and busulfan; and

salts, pharmaceutical derivatives, and a mixture thereof.

3. The method of claim 2, wherein the sparingly water-soluble drug is selected from the group consisting of naproxen, tacrolimus, valsartan, simvastatin, fenofibrate, itraconazole, biphenyl dimethyl dicarboxylate, silymarin, sopharcone, pantoprazole, cilostazol, and salts, pharmaceutical derivatives and a mixture thereof.

4. The method of claim 1, which further comprises the step of treating the sparingly water-soluble drug to form particles having an average particle size of less than 100 μ

m, before conducting step

     1).

5. The method of claim 1, wherein the particles of sparingly water-soluble drug is contained in an amount ranging from 0.1 to 60% by weight in the saturated aqueous solution containing the dispersion agent.

6. The method of claim 1, wherein the surface stabilizer is selected from the group consisting of sodium dodecylsulfate, sodium dioctyl sulfosuccinate, lecithin, phospholipid, polyoxyethylene sorbitan fatty acid ester, potassium sorbate, poloxamer, prophylene glycol, methyl cellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, benzethonium chloride, benzalkonium chloride, sorbic acid, benzoic acid, sodium benzoate, propylparaben, methylparaben, polyvinylalcohol, polyvinylpyrrolidone, alginic acid, sodium alginate and a mixture thereof.

7. The method of claim 6, wherein the surface stabilizer is selected from the group consisting of hydroxypropyl cellulose, poloxamer, polyvinylpyrrolidone and a mixture thereof.

8. The method of claim 1, wherein the surface stabilizer is used in an amount ranging from 0.0001 to 90% by weight based on the weight of the sparingly water-soluble drug.

9. The method of claim 1, wherein the dispersion agent is selected from the group consisting of monosaccharides, disaccharides and trisaccharides including lactose, sucrose, raffinose, mannitol, trehalose, sorbitol, xylitol, glycerol, dextrose and fructose, and a mixture thereof.

10. The method of claim 1, wherein the dispersion agent is used in an amount ranging from 0.1 to 200% by weight based on the weight of the sparingly water-soluble drug.

11. The method of claim 1, wherein the mixing and grinding process in step 2) is conducted by wet grinding using a dispersion mill including a ball mill, an oscillating mill and a bead mill;

ultrasonic irradiation;

or hearing force grinding process.

12. The method of claim 1, wherein the homogenized dispersion obtained in step 2) has an apparent viscosity ranging from 1 to 100,000 centipoises.

13. The method of claim 1, wherein the centrifuging process in step 3) is conducted at a rate ranging from 500 to 200,000 rpm and a temperature ranging from 0 to 50°

C.

14. The method of claim 1, wherein the high-pressure filtering process in step 3) is conducted at a pressure ranging from 200 to 2000 mmHg and a temperature ranging from 0 to 50°

C.

15. The method of claim 1, wherein the drying process in step 3) is conducted by freeze drying or spray drying.

16. A powder composition comprising nanoparticles of a sparingly water-soluble drug prepared by the method according to claim 1, which shows a particle size distribution of 10 to 1000 nm for 10 to 90% of the drug particles determined based on a particle size normal distribution curve obtained for the powder and an average particle size of 10 to 400 nm in an aqueous medium.

17. A pharmaceutical composition comprising the powder composition of claim 16 together with a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17, which is of a preparation form selected from the group consisting of granules, powders, syrups, liquids, suspensions, tablets, capsules, troches or pills for oral administration, and transdermal systems, lotions, ophthalmic ointments, ointments, plasters and pressure sensitive adhesives, cataplasmas, creams, pastes, suspensions, liquids, injections or suppositories for parenteral administration.